Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Harvard Bioscience, Inc. (NASDAQ:HBIO - Get Rating) Director Bertrand Loy purchased 9,291 shares of the company's stock in a transaction dated Friday, August 26th. The shares were bought at an average price of $3.41 per share, for a total transaction of $31,682.31. Following the completion of the transaction, the director now directly owns 399,651 shares in the company, valued at approximately $1,362,809.91. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Bertrand Loy also recently made the following trade(s): On Wednesday, August 24th, Bertrand Loy purchased 17,291 shares of Harvard Bioscience stock. The shares were bought at an average price of $3.23 per share, for a total transaction of $55,849.93. On Monday, August 22nd, Bertrand Loy purchased 4,918 shares of Harvard Bioscience stock. The shares were bought at an average price of $3.16 per share, for a total transaction of $15,540.88. On Thursday, August 18th, Bertrand Loy purchased 1,151 shares of Harvard Bioscience stock. The shares were bought at an average price of $3.19 per share, for a total transaction of $3,671.69. Harvard Bioscience Stock Performance

HBIO traded up $0.02 during trading hours on Monday, hitting $3.31. The company's stock had a trading volume of 45,510 shares, compared to its average volume of 211,747. Harvard Bioscience, Inc. has a fifty-two week low of $3.10 and a fifty-two week high of $8.48. The company has a current ratio of 2.42, a quick ratio of 1.16 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $137.82 million, a PE ratio of -36.55 and a beta of 1.71. The company has a 50-day simple moving average of $3.55 and a 200 day simple moving average of $4.54.

Harvard Bioscience (NASDAQ:HBIO - Get Rating) last posted its earnings results on Wednesday, August 3rd. The medical instruments supplier reported $0.02 EPS for the quarter, beating the consensus estimate of $0.01 by $0.01. Harvard Bioscience had a positive return on equity of 7.74% and a negative net margin of 3.03%. The firm had revenue of $29.21 million for the quarter, compared to analysts' expectations of $30.10 million. As a group, sell-side analysts expect that Harvard Bioscience, Inc. will post 0.05 EPS for the current year. Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on HBIO shares. KeyCorp dropped their price target on Harvard Bioscience from $10.00 to $7.00 and set an "overweight" rating on the stock in a research report on Friday, August 5th. TheStreet cut Harvard Bioscience from a "c" rating to a "d+" rating in a research report on Monday, May 23rd.Hedge Funds Weigh In On Harvard Bioscience

Hedge funds have recently modified their holdings of the company. Amalgamated Bank bought a new stake in shares of Harvard Bioscience during the 1st quarter worth $38,000. Lazard Asset Management LLC boosted its stake in shares of Harvard Bioscience by 230.5% during the 1st quarter. Lazard Asset Management LLC now owns 7,120 shares of the medical instruments supplier's stock worth $44,000 after acquiring an additional 4,966 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in shares of Harvard Bioscience by 47.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,920 shares of the medical instruments supplier's stock worth $36,000 after acquiring an additional 3,200 shares in the last quarter. Empirical Asset Management LLC bought a new stake in shares of Harvard Bioscience during the 2nd quarter worth $36,000. Finally, Prudential Financial Inc. bought a new stake in shares of Harvard Bioscience during the 2nd quarter worth $37,000. 72.75% of the stock is currently owned by institutional investors and hedge funds. Harvard Bioscience Company Profile (Get Rating)

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.Featured ArticlesGet a free copy of the StockNews.com research report on Harvard Bioscience (HBIO)What is the NASDAQ Stock Exchange?Should You Be Bullish On Barrick Gold?The Institutions Choose Dollar General For The 2nd Half The S&P 500 Just Flashed A Significant Signal Why Trading Volume is Unusually High on These 3 Stocks

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Harvard Bioscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harvard Bioscience wasn't on the list.

While Harvard Bioscience currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Tom remains optimistic about investors’ prospects going forward, even as the market reacts to the words of Fed Chair Jerome Powell about “pain ahead.”

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.